Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
Bitwise MARA Option Income Strategy ETF (IMRA) reports fund updates tied to monthly distributions for Bitwise's Option Income Strategy ETF suite. News for the fund centers on distribution per share, distribution rate, 30-day SEC yield, payment dates, return of capital treatment, expenses, and performance periods.
Fund updates also describe risks associated with the option-income approach, including derivative instruments, leverage, issuer-specific volatility, and differences between derivatives and direct holdings of traditional securities.
Imara Inc. (Nasdaq: IMRA) announced the dosing of the first patient in its Ardent Phase 2b clinical trial of IMR-687 for adult sickle cell disease (SCD) patients. The trial aims to evaluate higher doses of IMR-687, specifically 300 mg and potentially 400 mg, compared to a placebo, aiming for a significant increase in fetal hemoglobin (HbF) levels. Previous interim results from a Phase 2a trial indicated well-tolerated results, showing a statistically significant increase in F-cells. Top-line data from the Phase 2a trial is expected in Q4 2020.
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on August 14, 2020, at 8:30 a.m. ET to discuss Q2 2020 financial results and business updates. This clinical-stage biopharmaceutical company focuses on developing therapeutics for rare genetic disorders of hemoglobin. Its lead candidate, IMR-687, is a small molecule inhibitor designed for sickle cell disease and beta-thalassemia treatment. Investors can access the webcast on the Imara website, and further details are available through investor relations contacts.
IMARA (Nasdaq: IMRA) announced that the FDA has granted Fast Track and Rare Pediatric Disease designations for its drug IMR-687, aimed at treating beta-thalassemia. These designations facilitate expedited development and review processes. IMARA recently commenced a Phase 2b clinical trial for IMR-687 in adult patients and plans to initiate pediatric testing soon. Previously, IMR-687 received Orphan Drug designation for both beta-thalassemia and sickle cell disease. These advancements underline IMARA's commitment to develop effective treatments for rare genetic disorders.
Imara Inc. (Nasdaq: IMRA) announced its addition to the U.S. small-cap Russell 2000 Index, effective July 1, 2020, following its IPO in March. This inclusion is significant as approximately $9 trillion is benchmarked against Russell U.S. Indexes, enhancing the visibility and credibility of Imara in the investment community. The company is advancing IMR-687, a treatment for blood disorders, with expectations of continued growth. Imara aims to create value for patients and shareholders through its ongoing developments in innovative therapeutics.
IMARA Inc. (Nasdaq: IMRA) announced its 'Real Impact' initiative, providing grants to community organizations addressing the needs of patients with sickle cell disease (SCD) and beta-thalassemia. Originally planning to fund 20 grants, they increased the number to 25 due to heightened demand, especially for COVID-19 relief efforts. The company assessed grant applications based on community impact and execution plans. Nineteen grants will focus on COVID-19 relief, while others support social health and organizational enhancements.
IMARA Inc. (Nasdaq: IMRA) has received Orphan Drug Designation from the FDA for IMR-687, aimed at treating beta-thalassemia, following prior designation for sickle cell disease. This recognition emphasizes the need for innovative treatments for rare blood disorders. The company has initiated its Phase 2b clinical trial in the U.S., with plans for global regulatory submissions. IMR-687, a potent PDE9 inhibitor, increases cGMP levels which may help reactivate fetal hemoglobin, potentially improving patient outcomes.
Imara presented interim results from its Phase 2a trial of IMR-687 for sickle cell disease at the EHA Annual Congress. The data showed a statistically significant increase in fetal hemoglobin (HbF) and F-cells in high-dose groups after 24 weeks of treatment. IMR-687 was well tolerated both as monotherapy and with hydroxyurea. Following positive outcomes, a Phase 2b clinical trial will be initiated to explore higher doses over a year. The results suggest IMR-687 could be a promising oral therapy for sickle cell disease, with anticipated improvements in patient outcomes.
Imara Inc. (Nasdaq: IMRA) announced the presentation of interim data from its Phase 2a study of IMR-687 for sickle cell disease at the 25th Annual EHA Congress from June 11-21, 2020. The data will be presented by Dr. Biree Andemariam and will focus on IMR-687's efficacy in increasing F-Cells and fetal hemoglobin. The session will be accessible on-demand starting June 12, 2020, with top-line data expected in Q4 2020. IMR-687 is a potent PDE9 inhibitor aimed at improving blood flow and reducing symptoms in patients with sickle cell disease and beta-thalassemia.
Summary not available.